Mangiferin mitigates diabetic cardiomyopathy in streptozotocin-diabetic rats

Canadian Journal of Physiology and Pharmacology

Volumn 91, Issue 9, 2013, Pages 759-763

  Hou, Jun ^a   Zheng, Dezhi ^b   Zhong, Guocheng ^c   Hu, Yonghe ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b 71602 Medical Crop of People's Liberation Army ^*  (China)

^c 452nd Hospital of People's Liberation Army   (China)

Author keywords

Diabetic cardiomyopathy; Left ventricular remodeling; Mangiferin; Myocardial fibrosis

Indexed keywords

COLLAGEN; GELATINASE A; GELATINASE B; MANGIFERIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; CARDIOTONIC AGENTS; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DIET, HIGH-FAT; FIBROSIS; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING; XANTHONES;

EID: 84883261320     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2013-0090     Document Type: Article

References (19)

1. Ernande, L., Bergerot, C., Rietzschel, E.R., De Buyzere, M.L., Thibault, H., Pignonblanc, P.G., et al. 2011. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J. Am. Soc. Echocardiogr. 24(11): 1268-1275. doi:10.1016/j.echo.2011.07.017.
2. Hou, J., Zheng, D.Z., Zhou, J.Y., and Zhou, S.W. 2010. Orexigenic effect of cocaineand amphetamine-regulated transcript (CART) after injection into hypothalamic nuclei in streptozotocin-diabetic rats. Clin. Exp. Pharmacol. Physiol. 37(10): 989-995. doi:10.1111/j.1440-1681.2010.05423.x.
3. Hou, J., Zheng, D.Z., Fan, K.H., Yu, B.T., Xiao, W.J., Ma, J., et al. 2012. Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats. Pharmacology, 90(3-4): 177-182. doi:10.1159/000342128.
4. ILAR (Institute of Laboratory Animal Resources). 2010. Guide for the Care and Use of Laboratory Animals. NIH Publication No. 85-23 (revised 1996). National Academy Press, Washington, D.C. Available from http://www.nap.edu/catalog.php?record_id=12910.
5. Leiro, J.M., Alvarez, E., Arranz, J.A., Siso, I.G., and Orallo, F. 2003. In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factor-alpha and transforming growth factor-beta genes. Biochem. Pharmacol. 65(8): 1361-1371. doi:10.1016/S0006-2952(03)00041-8.
6. Mano, Y., Anzai, T., Kaneko, H., Nagatomo, Y., Nagai, T., Anzai, A., et al. 2011. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Cir. J. 75(7): 1717-1727. doi:10.1253/circj.CJ-10-1199.
7. Muruganandan, S., Gupta, S., Kataria, M., Lal, J., and Gupta, P.K. 2002. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology, 176(3): 165-173. doi:10.1016/S0300-483X(02) 00069-0.
8. Muruganandan, S., Srinivasan, K., Gupta, S., Gupta, P.K., and Lal, J. 2005. Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J. Ethnopharmacol. 97(3): 497-501. doi:10.1016/j.jep.2004.12.010.
9. Poornima, I.G., Parikh, P., and Shannon, R.P. 2006. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98(5): 596-605. doi:10.1161/01.RES.0000207406.94146.c2.
10. Prabhu, S., Jainu, M., Sabitha, K.E., and Devi, C.S. 2006. Cardioprotective effect of mangiferin on isoproterenol induced myocardial infarction in rats. Indian J. Exp. Biol. 44(3): 209-215.
11. Studholme, D.J., and Buck, M. 2000. The biology of enhancer-dependent transcriptional regulation in bacteria: insights from genome sequences. FEMS. Microbiol. Lett. 186(1): 1-9. doi:10.1111/j.1574-6968.2000.tb09074.x.
12. Ti, Y., Xie, G.L., Wang, Z.H., Bi, X.L., Ding, W.Y., Wang, J., et al. 2011. TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model. Diabetes, 60(11): 2963-2974. doi:10.2337/db11-0549.
13. Van Linthout, S., Seeland, U., Riad, A., Eckhardt, O., Hohl, M., Dhayat, N., et al. 2008. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res. Cardiol. 103(4): 319-327. doi:10.1007/s00395-008-0715-2.
14. Vu, T.H., and Werb, Z. 2000. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14(17): 2123-2133. doi:10.1101/gad.815400.
15. Wang, Y., Su, Y., Xu, Y., Pan, S.H., and Liu, G.D. 2010. Genetic polymorphism c.1562C>T of the MMP-9 is associated with macroangiopathy in type 2 diabetes mellitus. Biochem. Biophys. Res. Commun. 391(1): 113-117. doi:10.1016/j.bbrc.2009.11.012.
16. Yarbrough, W.M., Mukherjee, R., Brinsa, T.A., Dowdy, K.B., Scott, A.A., Escobar, G.P., et al. 2003. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J. Thorac. Cardiovasc. Surg. 125(3): 602-610. doi:10.1067/mtc.2003.197.
17. Yin, H.Q., Wang, B., Zhang, J.D., Lin, H.Q., Qiao, Y., and Wang, R. 2008. Effect of traditional Chinese medicine Shu-Mai-Tang on attenuating TNF alphainduced myocardial fibrosis in myocardial ischemia rats. J. Ethnopharmacol. 118(1): 133-139. doi:10.1016/j.jep.2008.03.022.
18. Zhang, S., Li, H., and Yang, S.J. 2010. Tribulosin protects rat hearts from ischemia/ reperfusion injury. Acta Pharmacol. Sin. 31(6): 671-678. doi:10.1038/aps.2010.45.
19. Zheng, D.Z., Hou, J., Xiao, Y.B., Zhao, Z., and Chen, L. 2012. Cardioprotective effect of mangiferin on left ventricular remodeling in rats. Pharmacology, 90(1-2): 78-87. doi:10.1159/000339450.